Generex announces new clinical trial of Hema Diagnostic Systems’ Rapid 1-2-3® TB point-of-care tests

MIRAMAR, Fla., September 20, 2017--Generex Biotechnology Corporation (OTCPink:GNBT) (www.generex.com) today announced the participation by its subsidiary, Hema Diagnostic Systems LLC (www.hemadiagnosticsystems.com), in a diagnostic clinical trial for tuberculosis in Sub-Saharan African countries. The trial is being conducted by a number of international collaborating institutions and the results of the trial will determine the accuracy and clinical utility of the Rapid 1-2-3^® Hema Tuberculosis EXPRESS^® TB-XT and the Rapid 1-2-3^® Hema Tuberculosis EXPRESS^® TB-XT3 point-of-care tests as primary triage assays for the presence of active tuberculosis, or as part of a combination of tests used for that purpose.